UK Pharmaceutical Market Overview:
The UK pharmaceutical market size reached USD 38.82 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 73.19 Billion by 2032, exhibiting a growth rate (CAGR) of 6.70% during 2024-2032. The heightened prevalence of chronic diseases among the masses, rising advancements in personalized medicine and bioengineering, and implementation of favorable government policies are some of the factors supporting the growth of the market.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023 |
USD 38.82 Billion |
Market Forecast in 2032 |
USD 73.19 Billion |
Market Growth Rate 2024-2032 |
6.70% |
UK Pharmaceutical Market Trends:
Advancements in Biotechnology and Personalized Medicine
Bioengineering and personalized medical technologies are growing rapidly in the UK. These trends are improving efficiency in the healthcare industry by offering individualized treatment plans developed from personal genetic profiles. These advancements create precision medicine treatment options that improve efficacy and reduce negative side effects. In 2024, the NHS treated its first patient in England with a personalized vaccine targeting bowel cancer, as part of a clinical trial. Personalized medicine is revolutionizing how complex diseases, such as cancer and autoimmune disorders, are treated, aligning with trends emphasizing precision over a one-size-fits-all approach. The expansion of biotechnology companies and investments in research and development (R&D) is leading to an increase in biotech-related investments.
Aging Population and Chronic Disease Prevalence
The UK's aging population is a primary driver of pharmaceutical demand, particularly in areas related to chronic diseases, such as cardiovascular disorders, diabetes, and neurodegenerative conditions. As per the Office for National Statistics (ONS), over the next 15 years, the size of the UK population aged 85 years and above is expected to increase from 1.6 million to 2.6 million, leading to an increased demand for long-term medications and treatments. In response, pharmaceutical companies are launching several age-targeted drugs in recent years. Moreover, pharmaceutical companies are launching drugs for the treatment of hyperkalemia, which primarily affects older adults with kidney issues. The rise in conditions like Alzheimer's, Parkinson’s, and heart disease is influencing the development of innovative therapies. This demographic shift is catalyzing the demand on healthcare services and pharmaceutical companies to produce more targeted and effective treatments.
Government Policies and Healthcare Reforms
Government initiatives and healthcare reforms play a crucial role in bolstering the market growth in the UK. The UK government’s focus on accelerating drug approvals and enhancing access to medicines is creating a favorable environment for pharmaceutical companies. The government provided £200 million to the NHS in January 2023 to fund step-down capacity and £50 million in capital spending to expand the discharge lounges and ambulance hubs in hospitals. Additionally, the Department of Health and Social Care (DHSC) opened £400m investment program to fasten and enhance clinical trials in UK in 2024. This investment is considered to increase the UK’s capacity for clinical trials and provide researchers better access to the latest equipment and technology. As part of the program, up to 18 new ‘Commercial Research Delivery Centers’ will be opened across the UK, which will support patient recruitment into trials.
UK Pharmaceutical Market News:
- May 2024: Marksans Pharma obtained UK healthcare regulator’s nod for marketing new oral solution, Levetiracetam Relonchem 100 mg/mL. It will be used to treat epilepsy and help control certain seizures.
- August 2023: The state-run national health service in Britain will provide an injection that treats cancer of innumerable patients and cut treatment times by up to 3 quarters. The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the injection, and it will help in treating patients with immunotherapy and atezolizumab.
UK Pharmaceutical Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on type, routes of administration, distribution channel, and end user.
Type Insights:
- Pharmaceutical Drugs
- Cardiovascular Drugs
- Dermatology Drugs
- Gastrointestinal Drugs
- Genito-Urinary Drugs
- Hematology Drugs
- Anti-Infective Drugs
- Metabolic Disorder Drugs
- Musculoskeletal Disorder Drugs
- Central Nervous System Drugs
- Oncology Drugs
- Ophthalmology Drugs
- Respiratory Diseases Drugs
- Biologics
- Monoclonal Antibodies (MAbS)
- Therapeutic Proteins
- Vaccines
The report has provided a detailed breakup and analysis of the market based on the type. This includes pharmaceutical drugs (cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal disorder drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs) and biologics (monoclonal antibodies (MAbS), therapeutic proteins, and vaccines).
Routes of Administration Insights:
- Oral
- Topical
- Parenteral
- Others
A detailed breakup and analysis of the market based on the routes of administration have also been provided in the report. This includes oral, topical, parenteral, and others.
Distribution Channel Insights:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacy, retail pharmacy, and online pharmacy.
End User Insights:
- Hospitals and ASCs
- Clinics
- Others
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospital and ASCs, clinics, and others.
Regional Insights:
- London
- South East
- North West
- East of England
- South West
- Scotland
- West Midlands
- Yorkshire and The Humber
- East Midlands
- Others
The report has also provided a comprehensive analysis of all the major regional markets, which include London, South East, North West, East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, and Others.
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
UK Pharmaceutical Market Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
USD Billion |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
- Type
- Routes of Administration
- Distribution Channel
- End User
- Region
|
Types Covered |
- Pharmaceutical Drugs: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs
- Biologics: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
|
Routes of Administrations Covered |
Oral, Topical, Parenteral, Others |
Distribution Channels Covered |
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy |
End Users Covered |
Hospital and ASCs, Clinics, Others |
Regions Covered |
London, South East, North West, East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, Others. |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the UK pharmaceutical market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the UK pharmaceutical market?
- What is the breakup of the UK pharmaceutical market on the basis of type?
- What is the breakup of the UK pharmaceutical market on the basis of routes of administration?
- What is the breakup of the UK pharmaceutical market on the basis of distribution channel?
- What is the breakup of the UK pharmaceutical market on the basis of end user?
- What are the various stages in the value chain of the UK pharmaceutical market?
- What are the key driving factors and challenges in the UK pharmaceutical?
- What is the structure of the UK pharmaceutical market and who are the key players?
- What is the degree of competition in the UK pharmaceutical market?
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the UK pharmaceutical market from 2018-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the UK pharmaceutical market.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the UK pharmaceutical industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.